Literature DB >> 9195069

The contribution of fluconazole to the changing epidemiology of invasive candidal infections.

M H White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9195069     DOI： 10.1086/513661

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  16 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Authors:  Benito Almirante; Dolors Rodríguez; Benjamin J Park; Manuel Cuenca-Estrella; Ana M Planes; Manuel Almela; Jose Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Pere Saballs; Scott K Fridkin; Juliette Morgan; Juan L Rodriguez-Tudela; David W Warnock; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Use of antifungal agents in pediatric and adult high-risk areas.

Authors:  E Ramírez; J García-Rodríguez; A M Borobia; J M Ortega; S Lei; A Barrios-Fernández; M Sánchez; A J Carcas; A Herrero; J M de la Puente; J Frías
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-01       Impact factor: 3.267

4.  Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006.

Authors:  Shawn R Lockhart; Debra Wagner; Naureen Iqbal; Peter G Pappas; David R Andes; Carol A Kauffman; Lisa M Brumble; Susan Hadley; Randall Walker; James I Ito; John W Baddley; Tom Chiller; Benjamin J Park
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

5.  Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Authors:  Michael Y Lin; Yehuda Carmeli; Jennifer Zumsteg; Ernesto L Flores; Jocelyn Tolentino; Pranavi Sreeramoju; Stephen G Weber
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia.

Authors:  Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

7.  No increase in frequency of antifungal resistance among yeasts isolated from normally sterile sites in patients at Foothills Hospital from 1993 to 1996.

Authors:  A P Gibb; C Thorson; H van den Elzen
Journal:  Can J Infect Dis       Date:  1999-01

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients.

Authors:  C A Mullen; H Abd El-Baki; H Samir; J J Tarrand; K V Rolston
Journal:  Support Care Cancer       Date:  2003-03-11       Impact factor: 3.603

10.  Blood stream infections by Candida glabrata and Candida krusei: a single-center experience.

Authors:  Hee Kyoung Choi; Su Jin Jeong; Han Sung Lee; Bum Sik Chin; Suk Hoon Choi; Sang Hoon Han; Myung Soo Kim; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.